By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ceregene, Inc. 

9381 Judicial Drive
Suite 130
San Diego  California  92121  U.S.A.
Phone: 858-458-8800 Fax: 858-458-8801



Company News
Sangamo BioSciences, Inc. (SGMO) to Acquire Ceregene, Inc. 8/27/2013 6:45:41 AM
Ceregene, Inc. Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5/21/2013 10:17:28 AM
Ceregene, Inc. Reports Data From Parkinson's Disease Phase 2b Study 4/22/2013 9:56:37 AM
Ceregene, Inc. and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial 3/13/2013 9:49:03 AM
Ceregene, Inc. Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin) 5/17/2012 1:01:13 PM
Ceregene, Inc. Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 12/1/2011 12:29:34 PM
Ceregene, Inc. Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 2/15/2011 7:22:25 AM
Ceregene, Inc. Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease 2/3/2011 7:12:49 AM
Ceregene, Inc. Raises $11.5 Million in Series D Financing 11/11/2010 6:20:30 AM
Ceregene, Inc. Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 10/20/2010 7:40:43 AM